Jacob Kimmel, co-founder and President of NewLimit, joins us to talk about the company’s newly announced $130 million Series B and its ambitious plan to develop reprogramming-based medicines that can reverse cellular aging.

We explore how NewLimit’s therapies use mRNA to deliver transcription factors that restore liver cells to a younger state, why the company is targeting alcohol-related liver disease first, and how advances in single-cell sequencing and AI made this work possible. Jacob also shares how NewLimit is expanding into the immune and endothelial systems—and what that could mean for extending human healthspan.

We also covered OpenAI’s acquisition of Windsurf, DoorDash’s Deliveroo and SevenRooms deals, Legora’s new raise in legal AI, and Uber’s $700M push into Turkey’s delivery market.